课题基金 / 基金详情

Center for Pre-Clinical Cancer Research

Center for Pre-Clinical Cancer Research
临床前癌症研究中心
批准号:
10360591
负责人:
JOSEPH FRANCIS
金额:
$210.6万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-01 至 2026-02-28

项目摘要

项目成果

JOSEPH FRANCIS的其他基金

相似基金

相关文献

中文摘要
翻译
总结总体核心。 临床前癌症研究中心(癌症中心)致力于在临床上识别 使用与疾病密切相关的模型研究人类癌症疾病的相关机制 在肿瘤微环境的背景下的状态。三维肿瘤培养的最新进展 技术已经加强了对体外人类细胞培养系统的关注,以揭示 对人类肿瘤发生的洞察,从而推动新的治疗发现。 有前途的初级调查人员(PJI)解决毁灭性的人类癌症疾病 在患者中表现出不良的结果,并且没有得到满足的治疗方法 需要。PJI的四个项目以骨肉瘤、乳腺癌、肝癌和 前列腺癌作为疾病将受益于临床前模型,这些模型 对人体机械效能的预测。所有的PJI项目都将在 体内小鼠模型和/或体外三维肿瘤球体识别相关机制 研究肿瘤发生或评估新的治疗策略。该中心将促进 通过建立一个新的专门的核心设施,建立一个统一和协调的办法, 临床评价核心(PCEC),为临床研究提供科学专业知识和技术支持 PJI项目的临床前评估。独特的PCEC将提供一个集中的 支持癌症的探索性和转化性评估的方法 人类的机制和治疗策略。为了实现这一方法,高级 3D细胞培养系统将提供关键的翻译信息。并弥合差距 动物模型和人类治疗结果之间的关系。新的分子生物学和 免疫病理核心(MBIPC)将提供最先进的设备和 分子生物学和免疫病理学方面的专业知识,同时利用广泛的资源, 路易斯安那州立大学支持向量机。人类和动物疾病是路易斯安那州立大学支持向量机和路易斯安那州立大学的主要焦点 校园里。该中心有三个目标:目标1.创建临床前癌症中心 研究以促进和支持集中管理和协调 肿瘤发生机制和转化性治疗的临床前评估 接近了。目标2.为科布雷PJI和其他调查人员提供核心 为晚期临床前癌症提供资源和支持的基础设施 将提高PJI个人对外部资金的竞争力的研究。目标 3.使用最先进的技术提供临床前评估的培训和指导 体外三维肿瘤球体补充体内肿瘤疾病模型。
英文摘要
Summary Overall Core. The Center for Pre-Clinical Cancer Research (Cancer COBRE) aims to identify clinically relevant mechanisms of human cancer disease using models that closely reflect the disease state in the context of the tumor microenvironment. Recent advances in 3D tumor culture techniques have intensified the focus on in vitro human cell culture systems to reveal insights into human tumorigenesis and thus drive novel therapeutic discovery. Promising Junior Investigators (PJIs) address devastating human cancer diseases that exhibit poor outcomes in patients and for which there are unmet therapeutic needs. The four PJI projects feature osteosarcoma, breast cancer, liver cancer, and prostate cancer as diseases that would benefit from pre-clinical models that are more predictive of mechanistic efficacy in humans. All of the PJI projects will use specialized in vivo mouse models and/or in vitro 3D tumor spheroids to identify relevant mechanisms of tumorigenesis or for evaluation of novel therapeutic strategies. The Center will promote a unified and coordinated approach by establishing a new specialized core facility, Pre- Clinical Evaluation Core (PCEC), to provide scientific expertise and technical support for the pre-clinical evaluation of the PJI projects. The unique PCEC will provide a centralized approach that will support exploratory and translational assessment of cancer disease mechanisms and therapeutic strategies in humans. To accomplish this approach, advanced 3D cell culture systems will provide critical translational information. and bridge the gap between animal models and human therapeutic outcomes. The new Molecular Biology and Immunopatholgy Core (MBIPC) will provide access to state-of-the-art equipment and expertise in Molecular Biology and Immunopathology while leveraging extensive resources at LSU SVM. Human and animal diseases are a major focus at the LSU SVM and on the LSU campus. The Center has three Aims: Aim 1. To create a Center for Pre-Clinical Cancer Research to promote and support centralized management and coordination of pre-clinical evaluation of tumorigenesis mechanisms and translational therapeutic approaches. Aim 2. To provide the COBRE PJIs and other investigators with a core infrastructure for resources and support for advanced pre-clinical cancer disease research that will enhance PJI individual competitiveness for extramural funding. Aim 3. To provide training and mentorship on pre-clinical evaluation using state-of-the-art in vitro 3D tumor spheroids to complement in vivo cance disease modeling.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Center for Pre-Clinical Cancer Research
Administration Core
Center for Pre-Clinical Cancer Research
Administration Core
海外基金